Is the Reason why BioLineRx Ltd. (NASDAQ: BLRX) stock was hitting the roof early in the Morning

DBGI Stock
DBGI Stock

BioLineRx Ltd. (NASDAQ: BLRX) stock is up nearly 28 percent to hit $4.3 in pre-market trading, considering the Bio-tech company’s lack of reports or news releases. And what do you want to discover? And why is today’s BLRX stock trending higher? Here’s the latest update for investors to learn about BioLineRx Ltd (NASDAQ: BLRX).

 An oncology-focused, late clinical-stage biotech firm officially posted and offered a corporate overview of its financial performance for the quarter ended September 30, 2020.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The company posted positive findings from a pre-planned interim review of the GENESIS Phase 3 stem cell mobilization motixafortide trial in multiple myeloma patients have been published. The Data Management Committee considered statistically relevant evidence supporting primary endpoint care of motixafortide and eventually released a recommendation to halt patient registration promptly. The research registration of 122 patients was performed according to the DMC guideline (instead of 177 as originally planned). SCM is the most successful registration route for the Company;

BLRX also reported initiation of the investigator-initiated Phase 2 analysis of motixafortide in conjunction with LIBTAYO and first-line PDAC chemotherapy. Columbia University is conducting the research;

Moreover, it reported initiation of a Phase 1b investigator-initiated analysis to test motixafortide in patients hospitalized with acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections, performed by Wolfson Medical Center in Holon, Israel;


Please enter your comment!
Please enter your name here